Season 11 · Episode 31
S11 Ep31: How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd
OncLive® On Air · OncLive® On Air
November 4, 20249m 41s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In today’s episode, supported by Coherus Biosciences, we had the pleasure of speaking with Tarek Mekhail, MD, MSC, FRCSI, FRCSEd, about the use of toripalimab-tpzi (Loqtorz) in patients with nasopharyngeal carcinoma. Dr Mekhail is the medical director of the Thoracic Cancer Program and the Associate Executive Director at the AdventHealth Cancer Institute in Orlando, Florida.
In our exclusive interview, Dr Mekhail discussed the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma, clinical successes with toripalimab in the first- and second-line nasopharyngeal carcinoma settings, and what the future looks like regarding immunotherapy in this disease.
In our exclusive interview, Dr Mekhail discussed the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma, clinical successes with toripalimab in the first- and second-line nasopharyngeal carcinoma settings, and what the future looks like regarding immunotherapy in this disease.